Passage Bio, Inc.
NCM: PASGLive Quote
📈 ZcoreAI Score
Our AI model analyzes Passage Bio, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get PASG Z-Score →About Passage Bio, Inc.
Healthcare
Biotechnology
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
📊 Fundamental Analysis
Passage Bio, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -113.8%, which indicates that capital utilization is currently under pressure.
At a current price of $9.89, PASG currently sits at the 32nd percentile of its 52-week range (Range: $5.12 - $20.00).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$31.73M
Trailing P/E
--
Forward P/E
-1.12
Beta (5Y)
1.76
52W High
$20.00
52W Low
$5.12
Avg Volume
44K
Day High
Day Low